These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29020217)

  • 1. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    van Griensven J; Mengesha B; Mekonnen T; Fikre H; Takele Y; Adem E; Mohammed R; Ritmeijer K; Vogt F; Adriaensen W; Diro E
    Front Cell Infect Microbiol; 2018; 8():94. PubMed ID: 29651411
    [No Abstract]   [Full Text] [Related]  

  • 5. Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.
    Chechi F; Corsi P; Bartolozzi D; Gaiera G; Bartoloni A; Zammarchi L
    Am J Trop Med Hyg; 2021 Nov; 106(2):639-642. PubMed ID: 34781255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia.
    Vogt F; Mengesha B; Asmamaw H; Mekonnen T; Fikre H; Takele Y; Adem E; Mohammed R; Ritmeijer K; Adriaensen W; Melsew Y; van Griensven J; Diro E
    Am J Trop Med Hyg; 2018 Oct; 99(4):957-966. PubMed ID: 30084342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Abongomera C; Diro E; Vogt F; Tsoumanis A; Mekonnen Z; Admassu H; Colebunders R; Mohammed R; Ritmeijer K; van Griensven J
    Clin Infect Dis; 2017 Oct; 65(10):1703-1710. PubMed ID: 29020196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.
    Goswami RP; Goswami RP; Basu A; Ray Y; Rahman M; Tripathi SK
    Am J Trop Med Hyg; 2017 Feb; 96(2):285-291. PubMed ID: 27879457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
    Patel TA; Lockwood DN
    Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
    Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
    Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.
    Cota GF; de Sousa MR; de Assis TSM; Pinto BF; Rabello A
    Acta Trop; 2017 Aug; 172():186-191. PubMed ID: 28501450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.
    Cota GF; de Sousa MR; de Mendonça AL; Patrocinio A; Assunção LS; de Faria SR; Rabello A
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2816. PubMed ID: 24743472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
    Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ
    AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.
    Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
    BMC Infect Dis; 2017 Feb; 17(1):152. PubMed ID: 28212625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.